^
    Apply
    Neoadjuvant Cadonilimab Combined With Perioperative Oxaliplatin Plus S1 for Diffuse or Mixed Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (NCT06949033)
    Phase 3
    Zuoyi Jiao
    Not yet recruiting
    Last update posted :
    04/29/2025
    Initiation :
    05/15/2025
    Primary completion :
    12/31/2028
    Completion :
    12/31/2030
    PD-L1
    |
    Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin • Kaitanni (cadonilimab)
    Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (NCT06925243)
    Phase 3
    Zuoyi Jiao
    Recruiting
    Last update posted :
    04/22/2025
    Initiation :
    04/15/2025
    Primary completion :
    12/31/2027
    Completion :
    12/31/2030
    PD-L1
    |
    Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin
    Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach (NCT04863430)
    Phase 2
    Peking University
    Withdrawn
    Last update posted :
    02/21/2025
    Initiation :
    05/11/2021
    Primary completion :
    07/06/2023
    Completion :
    07/06/2023
    HER-2 • GPC3 • SALL4
    |
    HER-2 positive • HER-2 negative
    |
    AiTan (rivoceranib) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur)
    Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) (LUNG-MAP SUB-STUDY) (NCT06031688)
    Phase 2
    SWOG Cancer Research Network
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    08/08/2024
    Primary completion :
    05/31/2028
    Completion :
    05/31/2029
    EGFR • HER-2 • KRAS • BRAF • ALK • MET • RET • ROS1 • NTRK
    |
    BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • HER-2 mutation • EGFR T790M • MET exon 14 mutation • ALK fusion • ROS1 fusion • RET rearrangement
    |
    Cyramza (ramucirumab) • Tepmetko (tepotinib)
    Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors (KEYNOTE-E34) (NCT05784688)
    Phase 1/2
    TiumBio Co., Ltd.
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    03/10/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2028
    EGFR • KRAS • BRAF • NRAS
    |
    BRAF V600E • HER-2 amplification • BRAF V600 • BRAF wild-type
    |
    Keytruda (pembrolizumab) • tosposertib (NCE 401)
    Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2) (NCT05980000)
    Phase 2
    Washington University School of Medicine
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    10/27/2023
    Primary completion :
    04/30/2028
    Completion :
    04/30/2031
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)
    Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer (SHR-1316-SCLC-LN-001) (NCT06480864)
    Phase N/A
    Yunpeng Liu
    Recruiting
    Last update posted :
    01/06/2025
    Initiation :
    08/09/2024
    Primary completion :
    08/01/2025
    Completion :
    08/01/2026
    PD-L1 • IL6 • IL10
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • AiTan (rivoceranib) • etoposide IV • AiRuiLi (adebrelimab)
    Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma (NCT04701060)
    Phase 2
    Tianjin Medical University Cancer Institute and...
    Completed
    Last update posted :
    12/03/2024
    Initiation :
    01/26/2021
    Primary completion :
    03/04/2024
    Completion :
    10/04/2024
    PD-L1
    |
    PD-L1 expression
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer (KEYNOTE-098) (NCT02443324)
    Phase 1
    Eli Lilly and Company
    Completed
    Last update posted :
    07/31/2024
    Initiation :
    07/29/2015
    Primary completion :
    08/31/2018
    Completion :
    04/12/2022
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)
    Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) (Lung-MAP Non-Matched Sub-Study) (NCT03971474)
    Phase 2
    SWOG Cancer Research Network
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    05/28/2019
    Primary completion :
    04/14/2022
    Completion :
    07/15/2024
    EGFR • BRAF • ALK • ROS1
    |
    BRAF V600E • EGFR mutation • BRAF V600 • EGFR T790M • ALK fusion • ROS1 fusion
    |
    Keytruda (pembrolizumab) • gemcitabine • docetaxel • Cyramza (ramucirumab) • pemetrexed • lexatumumab (ETR2-ST01)
    Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma (NCT06043427)
    Phase 2
    Canadian Cancer Trials Group
    Recruiting
    Last update posted :
    06/12/2024
    Initiation :
    04/16/2024
    Primary completion :
    12/31/2025
    Completion :
    06/30/2026
    HER-2
    |
    HER-2 positive
    |
    paclitaxel • Cyramza (ramucirumab) • Ziihera (zanidatamab-hrii)
    Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) (Lung-MAP Sub-Study) (NCT05642572)
    Phase 2
    SWOG Cancer Research Network
    Recruiting
    Last update posted :
    06/11/2024
    Initiation :
    05/05/2023
    Primary completion :
    05/31/2026
    Completion :
    05/31/2027
    EGFR • MET
    |
    EGFR mutation • MET amplification
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab) • Tabrecta (capmatinib)